Abstract | AIMS: IMPROVE is an open-label, multinational, non-randomised, 26-week observational study designed to evaluate the safety and effectiveness of biphasic insulin aspart 30 ( BIAsp 30) in routine clinical practice. Here, we report data for patients switching to BIAsp 30 from human premixed insulin. METHODS: Patients (n = 3856) with type 2 diabetes previously receiving human premixed insulin with or without oral antidiabetic drugs were eligible for inclusion. Demographic data, efficacy end-points (HbA(1c), fasting blood glucose and postprandial blood glucose) and safety end-points (serious adverse drug reactions, hypoglycaemia and adverse events) were collected at baseline and final visit. A subgroup analysis of mean dose change was also undertaken. RESULTS: Switching patients to BIAsp 30 resulted in significant improvements in glycaemic control combined with a reduced risk of hypoglycaemia. Patients who reached the HbA(1c) target (< 7%) had shorter diabetes duration, lower HbA(1c) at baseline and needed less insulin. Over 30% of patients were able to reach this target without experiencing hypoglycaemia over the 26-week period. Compared with asymmetric dose switching, unit-for-unit switching resulted in the highest proportion of patients reaching HbA(1c) target and incurred the least amount of dose titration. CONCLUSIONS:
|
Authors | S Shah, M Benroubi, V Borzi, J Gumprecht, R Kawamori, J Shaban, M Shestakova, Y Wenying, P Valensi, IMPROVE Study Group Expert Panel |
Journal | International journal of clinical practice
(Int J Clin Pract)
Vol. 63
Issue 4
Pg. 574-82
(Apr 2009)
ISSN: 1742-1241 [Electronic] India |
PMID | 19210701
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biphasic Insulins
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin
- hemoglobin A1c protein, human
- insulin aspart, insulin aspart protamine drug combination 30:70
- Insulin, Isophane
- Insulin Aspart
|
Topics |
- Aged
- Biphasic Insulins
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Female
- Glycated Hemoglobin
(analysis)
- Humans
- Hypoglycemia
(prevention & control)
- Hypoglycemic Agents
(administration & dosage, adverse effects)
- Insulin
(administration & dosage, adverse effects, analogs & derivatives)
- Insulin Aspart
- Insulin, Isophane
- Male
- Middle Aged
- Patient Satisfaction
- Risk Factors
- Treatment Outcome
|